Sharp Services, a provider of contract packaging and clinical supply services, has announced an expansion of its Macungie facility in Pennsylvania, US.

This development aims to bolster the company’s production capacity for sterile injectables secondary packaging, responding to the increasing market demand.

The Macungie site, located in the heart of the US East Coast’s biopharma community, is currently equipped to offer pharmaceutical primary and secondary packaging services.

Sharp expects the expansion to enhance its secondary packaging capabilities, including vial labelling, autoinjector/pen assembly and labelling, injectables kitting, and prefilled syringe assembly and labelling.

These services are for pharmaceutical and biotech companies seeking reliable packaging solutions.

Sharp CCO Jeff Benedict said: “Demand for sterile injectable medicines has skyrocketed over the last few years due to increased investment in the biologics industry across all therapeutic categories, rare and orphan disease therapies, and blockbuster GLP-1 agonists.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The Macungie site expansion will create 157,500ft² of additional space, resulting in a total area of 315,000ft². This will take Sharp’s global footprint to more than 1.7 million square feet.

Sharp CEO Kevin Orfan said: “With this expansion, the Macungie site will double in size allowing Sharp to offer additional capacity and capabilities for our biopharma clients for complex biologics and small-molecule injectable medicines.”

The expansion plan will include the construction and fit-out of new packaging suites, cold storage rooms, and ambient warehouse space.

It will also include the installation of equipment and technology to support the assembly, labelling, and packaging of injectables.

Orfan added: “Once the GMP [good manufacturing practice] infrastructure is in place, we anticipate adding 75-100 colleagues to the Sharp team.” 

Recently, Sharp Services commissioned a new 660-pallet cold storage facility, maintaining temperatures between 2-8°C.